iodixanol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
iodine-containing contrast media	3302	92339-11-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: iodixanol visipaque	dimeric contrast media; structure given in first source Molecular weight: 1550.19 Formula: C35H44I6N6O15 CLOGP: -4.28 LIPINSKI: 3 HAC: 21 HDO: 13 TPSA: 339.09 ALOGS: -3.92 ROTB: 22

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iodixanol
visipaque

dimeric contrast media; structure given in first source

Molecular weight: 1550.19
Formula: C35H44I6N6O15
CLOGP: -4.28
LIPINSKI: 3
HAC: 21
HDO: 13
TPSA: 339.09
ALOGS: -3.92
ROTB: 22

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.44 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 22, 1996	FDA	GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pruritus	171.54	40.27	119	1969	283449	50319587
Urticaria	137.70	40.27	78	2010	129483	50473553
Acute generalised exanthematous pustulosis	98.15	40.27	29	2059	8909	50594127
Erythema	93.91	40.27	64	2024	146350	50456686
Contrast encephalopathy	88.37	40.27	12	2076	56	50602980
Rash maculo-papular	60.69	40.27	27	2061	26614	50576422
Anaphylactoid shock	56.40	40.27	10	2078	308	50602728
Rash pustular	53.92	40.27	17	2071	6464	50596572
Rash	53.60	40.27	77	2011	437394	50165642
Anaphylactoid reaction	50.61	40.27	14	2074	3392	50599644
Contrast media reaction	50.44	40.27	11	2077	996	50602040

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contrast media reaction	237.18	39.11	43	2320	762	29571402
Pruritus	180.42	39.11	113	2250	116736	29455428
Urticaria	167.10	39.11	83	2280	54577	29517587
Erythema	136.51	39.11	81	2282	75525	29496639
Contrast media allergy	95.58	39.11	18	2345	394	29571770
Rash	93.98	39.11	94	2269	189725	29382439
Anaphylactic reaction	93.35	39.11	45	2318	27528	29544636
Acute kidney injury	84.10	39.11	104	2259	265163	29307001
Acute generalised exanthematous pustulosis	64.31	39.11	22	2341	5561	29566603
Rash maculo-papular	43.54	39.11	26	2337	24263	29547901
Nephropathy toxic	40.75	39.11	19	2344	10737	29561427
Anaphylactoid reaction	40.35	39.11	12	2351	1933	29570231
Hypotension	39.83	39.11	62	2301	194292	29377872
Swelling face	39.66	39.11	23	2340	20327	29551837

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pruritus	324.88	36.41	223	4214	312177	64182118
Urticaria	280.29	36.41	155	4282	147162	64347133
Contrast media reaction	262.17	36.41	52	4385	1760	64492535
Erythema	211.29	36.41	141	4296	186929	64307366
Acute generalised exanthematous pustulosis	152.48	36.41	51	4386	14007	64480288
Rash	134.90	36.41	161	4276	458388	64035907
Acute kidney injury	108.41	36.41	143	4294	449097	64045198
Anaphylactic reaction	102.72	36.41	62	4375	68602	64425693
Rash maculo-papular	87.64	36.41	49	4388	46977	64447318
Contrast media allergy	83.36	36.41	21	4416	2120	64492175
Contrast encephalopathy	80.45	36.41	13	4424	130	64494165
Anaphylactoid reaction	79.57	36.41	24	4413	4714	64489581
Anaphylactoid shock	70.08	36.41	15	4422	739	64493556
Eosinophilia	66.40	36.41	38	4399	38038	64456257
Angioedema	63.24	36.41	44	4393	61777	64432518
Toxic skin eruption	58.80	36.41	28	4409	19256	64475039
Swelling face	57.93	36.41	41	4396	59125	64435170
Nephropathy toxic	55.14	36.41	26	4411	17488	64476807
Rash pustular	51.76	36.41	21	4416	9864	64484431
Dyspnoea	49.87	36.41	134	4303	718540	63775755
Hypotension	47.71	36.41	90	4347	380884	64113411
Flushing	47.59	36.41	41	4396	78607	64415688
Throat irritation	42.41	36.41	27	4410	32684	64461611
Nephropathy	41.12	36.41	17	4420	8369	64485926
Drug ineffective	40.88	36.41	5	4432	840242	63654053
Anaphylactic shock	39.23	36.41	25	4412	30303	64463992
Eyelid oedema	37.94	36.41	18	4419	12261	64482034
Sneezing	37.12	36.41	19	4418	15232	64479063

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08AB09	VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA	N0000010258	X-Ray Contrast Activity
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals
FDA EPC	N0000180185	Radiographic Contrast Agent
CHEBI has role	CHEBI:37338	contrast media

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.43	acidic
pKa2	10.85	acidic
pKa3	11.21	acidic
pKa4	11.63	acidic
pKa5	12.19	acidic
pKa6	13.65	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4020982	VUID
N0000148453	NUI
D01474	KEGG_DRUG
4020982	VANDF
C0063757	UMLSCUI
CHEBI:31705	CHEBI
CHEMBL1200507	ChEMBL_ID
DB01249	DRUGBANK_ID
C044834	MESH_SUPPLEMENTAL_RECORD_UI
5692	INN_ID
HW8W27HTXX	UNII
3724	PUBCHEM_CID
27729	RXNORM
11441	MMSL
4902	MMSL
d04016	MMSL
006060	NDDF
353962003	SNOMEDCT_US
395750001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Visipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-2222	INJECTION, SOLUTION	270 mg	INTRAVASCULAR	NDA	28 sections
Visipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-2222	INJECTION, SOLUTION	270 mg	INTRAVASCULAR	NDA	28 sections
Visipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-2222	INJECTION, SOLUTION	270 mg	INTRAVASCULAR	NDA	28 sections
Visipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-2222	INJECTION, SOLUTION	270 mg	INTRAVASCULAR	NDA	28 sections
Visipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-2223	INJECTION, SOLUTION	320 mg	INTRAVASCULAR	NDA	31 sections
Visipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-2223	INJECTION, SOLUTION	320 mg	INTRAVASCULAR	NDA	31 sections
Visipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-2223	INJECTION, SOLUTION	320 mg	INTRAVASCULAR	NDA	31 sections
Visipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-2223	INJECTION, SOLUTION	320 mg	INTRAVASCULAR	NDA	31 sections
Visipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-2223	INJECTION, SOLUTION	320 mg	INTRAVASCULAR	NDA	31 sections